Clifford Swan Investment Counsel LLC Novo Nordisk A S Transaction History

Clifford Swan Investment Counsel LLC

$2.78 Billion
Q3 2024

A detailed history of Clifford Swan Investment Counsel LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Clifford Swan Investment Counsel LLC holds 193,763 shares of NVO stock, worth $19.9 Million. This represents 0.83% of its overall portfolio holdings.

Number of Shares

193,763

Previous 195,118 0.69%

Holding current value

$19.9 Million

Previous $27.9 Million 17.16%

% of portfolio

0.83%

Previous 1.05%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$119.07 - $145.42 $161,339 - $197,044	-1,355 Reduced 0.69%	193,763 $23.1 Million
Q2 2024 Aug 06, 2024	SELL	$122.71 - $146.91 $521,762 - $624,661	-4,252 Reduced 2.13%	195,118 $27.9 Million
Q1 2024 Apr 16, 2024	SELL	$102.11 - $135.92 $1.11 Million - $1.48 Million	-10,906 Reduced 5.19%	199,370 $25.6 Million
Q4 2023 Feb 06, 2024	SELL	$87.78 - $105.45 $157,213 - $188,860	-1,791 Reduced 0.84%	210,276 $21.8 Million
Q3 2023 Nov 09, 2023	BUY	$90.94 - $199.54 $9.57 Million - $21 Million	105,192 Added 98.43%	212,067 $19.3 Million
Q2 2023 Aug 03, 2023	SELL	$155.98 - $172.65 $248,788 - $275,376	-1,595 Reduced 1.47%	106,875 $17.3 Million
Q1 2023 May 05, 2023	SELL	$132.34 - $159.14 $275,399 - $331,170	-2,081 Reduced 1.88%	108,470 $17.3 Million
Q4 2022 Feb 02, 2023	SELL	$102.55 - $135.33 $167,669 - $221,264	-1,635 Reduced 1.46%	110,551 $15 Million
Q3 2022 Nov 04, 2022	SELL	$95.28 - $116.93 $172,933 - $212,227	-1,815 Reduced 1.59%	112,186 $11.2 Million
Q2 2022 Aug 04, 2022	SELL	$103.24 - $121.81 $23,745 - $28,016	-230 Reduced 0.2%	114,001 $12.7 Million
Q1 2022 May 03, 2022	SELL	$93.1 - $112.54 $41,243 - $49,855	-443 Reduced 0.39%	114,231 $12.7 Million
Q4 2021 Feb 11, 2022	SELL	$95.88 - $117.08 $121,767 - $148,691	-1,270 Reduced 1.1%	114,674 $12.8 Million
Q3 2021 Nov 02, 2021	BUY	$84.42 - $106.62 $70,490 - $89,027	835 Added 0.73%	115,944 $11.1 Million
Q2 2021 Aug 05, 2021	SELL	$67.66 - $84.76 $103,519 - $129,682	-1,530 Reduced 1.31%	115,109 $11.3 Million
Q1 2021 May 07, 2021	SELL	$67.06 - $75.82 $109,710 - $124,041	-1,636 Reduced 1.38%	116,639 $7.86 Million
Q4 2020 Feb 11, 2021	SELL	$63.89 - $73.8 $176,591 - $203,983	-2,764 Reduced 2.28%	118,275 $8.26 Million
Q3 2020 Oct 30, 2020	SELL	$63.69 - $70.22 $236,162 - $260,375	-3,708 Reduced 2.97%	121,039 $8.4 Million
Q2 2020 Aug 06, 2020	SELL	$58.54 - $67.94 $151,208 - $175,489	-2,583 Reduced 2.03%	124,747 $8.17 Million
Q1 2020 Apr 09, 2020	SELL	$49.46 - $64.78 $159,508 - $208,915	-3,225 Reduced 2.47%	127,330 $7.67 Million
Q4 2019 Jan 30, 2020	SELL	$49.86 - $58.26 $488,278 - $570,540	-9,793 Reduced 6.98%	130,555 $7.56 Million
Q3 2019 Nov 12, 2019	SELL	$47.54 - $53.43 $213,359 - $239,793	-4,488 Reduced 3.1%	140,348 $7.26 Million
Q2 2019 Aug 13, 2019	SELL	$46.79 - $52.47 $847,600 - $950,494	-18,115 Reduced 11.12%	144,836 $7.39 Million
Q1 2019 May 14, 2019	SELL	$46.36 - $52.63 $520,854 - $591,298	-11,235 Reduced 6.45%	162,951 $8.52 Million
Q4 2018 Feb 13, 2019	SELL	$41.54 - $47.25 $336,889 - $383,197	-8,110 Reduced 4.45%	174,186 $8.03 Million
Q3 2018 Nov 14, 2018	SELL	$46.76 - $51.24 $859,308 - $941,637	-18,377 Reduced 9.16%	182,296 $8.59 Million
Q2 2018 Aug 13, 2018	SELL	$44.29 - $50.42 $1.17 Million - $1.33 Million	-26,469 Reduced 11.65%	200,673 $9.26 Million
Q1 2018 May 09, 2018	SELL	$48.49 - $58.14 $2.54 Million - $3.05 Million	-52,478 Reduced 18.77%	227,142 $11.2 Million
Q4 2017 Feb 09, 2018	BUY	$47.53 - $53.73 $446,116 - $504,309	9,386 Added 3.47%	279,620 $15 Million
Q3 2017 Nov 13, 2017	SELL	$41.15 - $49.22 $238,464 - $285,229	-5,795 Reduced 2.1%	270,234 $13 Million
Q2 2017 Aug 11, 2017	BUY	N/A	276,029	276,029 $11.8 Million

Others Institutions Holding NVO

# of Institutions

1,952

Shares Held

320M

Call Options Held

5.49M

Put Options Held

7.78M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $232B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Clifford Swan Investment Counsel LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clifford Swan Investment Counsel LLC with notifications on news.

Account

Clifford Swan Investment Counsel LLC Novo Nordisk A S Transaction History